Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison
Authors:
- 9 January 2011
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 104 (1) , 351-356
Abstract
Glioblastoma (GBM) is rare in early adulthood and little information is available on this subgroup. We investigated whether young age (18–30 years) had an independent effect on survival. We retrospectively reviewed patients from two large databases: Radiation Therapy Oncology Group (RTOG) and American College of Surgeons National Cancer Data Base (NCDB). In the RTOG evaluation, we analyzed all eligible GBM cases from 17 RTOG studies from 1974 to 2002. All patients with GBM during 1985–1998 in the NCDB were examined for comparison. Patients were divided into three cohorts: ages 18–30, 31–49, and ≥50. Overall survival, as a function of age (discreet and continuous), was assessed. The RTOG review included 3,136 patients: 112 (3.6%) were 18–30, 780 (24.9%) were 31–49, and 2,244 (71.6%) were ≥50. The median survival times of the three groups were 21.0, 13.5, and 9.1 months (P < 0.0001). Significant improvement in survival for younger patients was demonstrated with adjustment for recursive partitioning analysis (RPA) class. Of the 37,260 patients analyzed in the NCDB, 796 (2.1%) were 18–30, 5,711 (15.3%) were 31–49, and 30,753 (82.5%) were ≥50. The median survival times of the three groups were 18.0, 12.8, and 6.3 months (P < 0.0001). Data were not available for RPA class from this series. GBM is rare in young adulthood, comprising 2.1–3.6% of our patients. They have superior survival, even when adjusted for RPA class. More investigations on the unique biologic and clinical characteristics of tumors in this population are needed.Keywords
This publication has 30 references indexed in Scilit:
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Long-term survival with glioblastoma multiformeBrain, 2007
- Characterization of Glioblastomas in Young AdultsBrain Pathology, 2006
- Cancer in 15- to 29-Year-Olds by Primary SiteThe Oncologist, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Long-Term Survivors of GlioblastomaThe Cancer Journal, 2003
- Application of the MRC brain tumour prognostic index to patients with malignant glioma not managed in randomised control trialJournal of Neurology, Neurosurgery & Psychiatry, 1998
- Long-Term Survival in Patients with Malignant AstrocytomaNeurosurgery, 1994
- Long-Term Survival in Patients with Glioblastoma MultiformeNeurosurgery, 1993